SOLICITATION NOTICE
Q -- Services regarding mutation analysis of the NF1 gene from Epstein-Barr virus (EBV) cell lines from patients participating in the Natural History Study and Longitudinal Assessment of Children, Adolescents, and Adults with Neurofibromatosis Type 1
- Notice Date
- 9/1/2010
- Notice Type
- Presolicitation
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-100221-AV
- Archive Date
- 10/1/2010
- Point of Contact
- Ashley L. Virts,
- E-Mail Address
-
virtsa@mail.nih.gov
(virtsa@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Pediatric Oncology Branch (POB) plans to procure on a sole source basis with The University of Alabama at Birmingham, Medical Genomics Laboratory; 720 20th Street South; Birmingham, AL 35204-0024 for services regarding mutation analysis of the NF1 gene from Epstein-Barr virus (EBV) cell lines from patients participating in the Natural History Study and Longitudinal Assessment of Children, Adolescents, and Adults with Neurofibromatosis Type 1. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1 (b) (1). The North American Industry Classification System Code is 621511 and the business size standard is $12.5M. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The period of performance shall be for five months from date of award. The Contractor shall determine mutation analysis in 84 samples of patients with NF1 using an RNA-based core assay. EBV cells lines derived from patient samples will be treated and have total RNA extracted and analyzed using RT-PCR. All alterations or mutations detected at cDNA level will be confirmed by analysis of the paired gDNA. The mutation analysis shall incorporate full assessment of the NF1 gene in each patient using complementary techniques to identify: frameshift, missense, deep intronic and as classic splice mutations as well as NF1 microdeletions and smaller deletions/ duplications affecting the NF1 gene. The University of Alabama at Birmingham, Medical Genomics Laboratory is the only known source to the NCI who can provide the RNA-based core assay at a higher sensitivity to provide the correct classification of mutation affecting splicing and avoid the detection of rare benign intrinsic variants with no significance towards the study. In addition, the Contractor shall complement the RNA-based approach with dosage analysis and Fluorescence in Situ Hybridization (FISH) techniques to provide direct sequencing of all exons within the sample. The University of Alabama currently holds more than 7000 samples for NF1 including 3600 positive and 3400 negative which allows the gene test to verify whether specific phenotypes have a different spectrum of mutations. No other source is known to the NCI that has a large sample in order to compare results with. This step is critical towards the mission of the POB to detect only those mutations that are relative towards the study. The University of Alabama at Birmingham, Medical Genomics Laboratory solely possesses the expertise and resources for scientific comparability in measuring mutation analysis of the NF1 gene from EBV cell lines. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI contracting office on or before 11:00 AM EST on September 16, 2010. No electronic capability statements will be accepted (i.e. email or fax), an original and one copy must be sent to the NCI contracting office to the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Ashley Virts, Contract Specialist at (301) 435-3817. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-100221-AV on all correspondences.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-100221-AV/listing.html)
- Record
- SN02263860-W 20100903/100901235439-0b3a7fc951d39bf5ed6a23657fcc3a14 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |